Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks

NCT00094523 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT00094523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00094523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIB/IV, Open-label, Multi-center Trial to Evaluate the Safety, Tolerability, and Efficiency of HIV-1 Infected Subjects Switching Their Current Protease-inhibitor Therapies for a Fosamprenavir Therapy Over 48 Weeks
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
December 14, 2004
Completion date
June 29, 2007
Enrollment
314 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus i